AbbVie’s combination treatment of ABT-493 and ABT-530 boasted high cure rates among all genotypes of hepatitis C virus (HCV) in a series of studies, HIVandHepatitis.com reports. Researchers from the Phase IIb SURVEYOR trials conducted various studies among people with genotypes 1 through 6 of hep C who were given the pangenotypic NS3/4A protease inhibitor ABT-493 and the pangenotypic NS5A inhibitor ABT-530; findings were presented at the 2016 Digestive Disease Week meeting in San Diego.
The SURVEYOR-1 trial initially included non-cirrhotic people with genotype 1 of hep C, who received 12 weeks of 200 or 300 milligrams of ABT-493 and 40 or 120 mg of ABT-530. Then the study tested eight weeks of the two drugs among non-cirrhotic people with genotype 1, as well as 12 weeks of treatment with cirrhotic people with genotype 1 and non-cirrhotic people with genotypes 4, 5 and 6.
The SURVEYOR-2 trial included non-cirrhotic people with genotype 2 and cirrhotic and non-cirrhotic people with genotype 3, including people who had not been treated before and those who did not respond to a previous treatment. They took ABT-493 and ABT-530 for eight or 12 weeks, with one arm of participants taking 12 weeks of treatment receiving ribavirin.
Researchers previously presented results from the two trials at the AASLD Liver Meeting in November 2015 The Digestive Week presentations looked at pooled results based on genotype.
Among those with genotypes 1 and 2 treated with 300 mg of ABT-493 and 120 mg of ABT-530 for eight weeks, 97 percent of those with genotype 1 and 98 percent of those with genotype 2 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure). Excluding the one person with genotype 1 who stopped treatment early because of an adverse health matter unrelated to hep C treatment and the one participant with genotype 2 lost to follow-up, the cure rate was 100 percent for both genotypes.
The treatment was generally safe and well tolerated. The most commonly reported adverse health events were fatigue and headache, which were mostly mild.
Among the treatment-naive participants with genotype 3 and no cirrhosis in SURVEYOR-2, who were treated with 300 mg of ABT-493 and 120 mg of ABT-530 for eight weeks, 97 percent were cured. One participant withdrew consent for the study after six weeks of treatment; excluding this person from the analysis, the cure rate was 100 percent.
Treatment in this group was also safe and well tolerated.
Among those with genotypes 4 through 6 in part two of the SURVEYOR-1 trial who were treated with 300 mg of ABT-493 and 120 mg of ABT-530 for 12 weeks, 100 percent were cured.
Yet again, treatment was safe and well tolerated.
ABT-493 and ABT-530 are now being researched in Phase III trials of eight or 12 weeks of treatment given to people with all six genotypes, including those with and without cirrhosis.
To read the HIVandHepatitis article, click here.